Key result
Pamatolol shows greater cardioselectivity than atenolol and metoprolol in rat tissues.
Why the study?
The comparative effects of atenolol, metoprolol, and pamatolol on cardiac and vascular beta-adrenoceptors in rats were examined to assess their cardioselectivity and intrinsic beta-stimulatory action.
Atenolol, metoprolol, and pamatolol are cardioselective beta-blockers devoid of intrinsic sympathomimetic activity, with pamatolol showing the highest selectivity in rat models.
No takes yet. Share an insight, caveat, or question.
Does not support clinical adoption of pamatolol; leaves open translation of rat selectivity to human beta-blockade.
Börje Johansson (1979) studied this question. Atenolol, metoprolol, and pamatolol was evaluated on Chronotropic atrial responses and inhibition of spontaneous contractions in portal veins (pA2 values). Atenolol, metoprolol, and pamatolol are cardioselective beta-adrenoceptor antagonists devoid of intrinsic beta-stimulatory action, with pamatolol showing greater selectivity in rat tissues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: